Select a medication above to begin.
Victoza
liraglutide
Black Box Warnings .
Thyroid C-cell Tumor Risk
contraindicated in pts w/ medullary thyroid carcinoma (MTC) hx or family hx, or in pts w/ multiple endocrine neoplasia syndrome type 2 (MEN 2); dose-related and duration-dependent incr. in thyroid C-cell tumor incidence observed in rodents, but human relevance unknown; uncertain value of routine serum calcitonin or thyroid ultrasound monitoring; advise pts of potential MTC risk and thyroid tumor sx (e.g., neck mass, dysphagia, dyspnea, persistent hoarseness)
Adult Dosing .
Dosage forms: INJ (pen): 6 mg per mL
Special Note
- [prescribing info]
- Info: see other injectable liraglutide product for FDA-approved weight management dosing
diabetes mellitus, type 2
- [1.2-1.8 mg SC qd]
- Start: 0.6 mg SC qd x1wk, then 1.2 mg SC qd, then may incr. to 1.8 mg SC qd after at least 1wk; Max: 1.8 mg/day; Info: retitrate from 0.6 mg SC qd if tx interrupted for >3 days
cardiovascular event risk reduction - DM type 2 pts w/ estab. cardiovascular dz
- [1.2-1.8 mg SC qd]
- Start: 0.6 mg SC qd x1wk, then 1.2 mg SC qd, then may incr. to 1.8 mg SC qd after at least 1wk if additional glycemic control needed; Max: 1.8 mg/day; Info: retitrate from 0.6 mg SC qd if tx interrupted for >3 days
renal dosing
- [see below]
- renal impairment: no adjustment
- HD/PD: not defined
hepatic dosing
- [no adjustment]
Peds Dosing .
- Dosage forms: INJ (pen): 6 mg per mL
diabetes mellitus, type 2
- [10 yo and older]
- Dose: 0.6-1.8 mg SC qd; Start: 0.6 mg SC qd, may incr. by 0.6 mg/day no more frequently than qwk; Max: 1.8 mg/day; Info: retitrate from 0.6 mg SC qd if tx interrupted for >3 days
renal dosing
- [see below]
- renal impairment: no adjustment
- HD/PD: not defined
hepatic dosing
- [no adjustment]